UTAH MEDICAL PRODUCTS Reports 4.2% Year-Over-Year Revenue Decrease, 2.4% Increase in Net Income for Q2 FY2023
August 9, 2023
☀️Earnings Overview
For the second quarter of FY2023, UTAH MEDICAL PRODUCTS ($NASDAQ:UTMD) reported total revenue of USD 12.9 million, representing a decrease of 4.2% compared to the same period in the previous year. Additionally, net income reached USD 4.2 million, an increase of 2.4%, when compared to the same quarter of FY2022. The results were reported on June 30th 2023.
Analysis
GoodWhale has conducted an analysis of the fundamentals of UTAH MEDICAL PRODUCTS. Their ‘Star Chart’ classification indicates that UTAH MEDICAL PRODUCTS is a ‘cow’, which we conclude has the track record of paying out consistent and sustainable dividends. Therefore, this company would be of interest to investors who prefer a low-risk, consistent income such as retirees or conservative portfolio managers. Additionally, UTAH MEDICAL PRODUCTS appears to be strong in asset, dividend, and profitability metrics but weak in growth metrics. Goodwhale’s health score of 10/10 for UTAH MEDICAL PRODUCTS indicates that the company is in good health and capable of sustaining future operations in times of crisis. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for UTMD. More…
| Total Revenues | Net Income | Net Margin |
| 51.91 | 17.25 | 32.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for UTMD. More…
| Operations | Investing | Financing |
| 23.02 | -0.82 | -5.48 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for UTMD. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 130.47 | 8.71 | 32.53 |
Key Ratios Snapshot
Some of the financial key ratios for UTMD are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 5.7% | 8.6% | 36.7% |
| FCF Margin | ROE | ROA |
| 43.1% | 10.1% | 9.1% |
Peers
Their products are used in a variety of medical applications including obstetrics, gynecology, neonatal care, and urology. The company has a long history dating back to the early 1900s, and their products are sold in over 50 countries around the world. Zhende Medical Co Ltd is a Chinese medical device company that specializes in the manufacturing of medical devices and equipment. They have a wide range of products that are used in different medical applications. Natus Medical Inc is a medical device company that specializes in the development, manufacturing, and marketing of products for the newborn care, neurology, sleep, and hearing markets. Treace Medical Concepts Inc is a medical device company that specializes in the development and marketing of products for the treatment of chronic pain.
– Zhende Medical Co Ltd ($SHSE:603301)
Zhende Medical Co Ltd is a medical company that provides healthcare services. The company has a market cap of 12.25B as of 2022 and a return on equity of 9.58%. The company operates in China and focuses on providing health services to patients in rural areas. The company also provides health insurance and medical assistance to rural residents.
– Natus Medical Inc ($NASDAQ:TMCI)
Treace Medical Concepts Inc is a medical device company that develops, manufactures, and markets orthopedic products. The company offers a range of products, including hip, knee, and extremity products, as well as sports medicine products. It has a market cap of 1.29B as of 2022 and a return on equity of -44.68%.
Summary
UTAH MEDICAL PRODUCTS has reported its earnings results for the second quarter of FY2023 with total revenue of USD 12.9 million, a decrease of 4.2% year over year, and net income of USD 4.2 million, an increase of 2.4% year over year. This indicates that the company is experiencing a decrease in revenue although it has increased its profits. Investors should analyze the company’s performance to determine if it is still a financially sound investment. They should consider the company’s current debt and future growth prospects.
The company’s balance sheet should be examined to determine if it is properly funded. Analysts should also investigate any potential risks or obstacles the company may face along the way. Overall, investors should assess UTAH MEDICAL PRODUCTS to determine if it is still a wise investment opportunity.
Related Posts
Recent Posts
